Praxis Precision Medicines Inc. (PRAX) PT Raised to $575 at Goldman Sachs
August 21, 2026 6:29 AM
Goldman Sachs analyst Kevin Strang raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $575.00 (from $470.00) while maintaining a Buy rating.
